Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations - Simply Wall St News
Puma Biotechnology
Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology
Puma Biotechnology Stock (NASDAQ:PBYI), Quotes and News Summary - Benzinga
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Should You Buy Puma Biotechnology Inc (PBYI) Stock After it Has Gained 6.09% in a Week?
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology Surging
Puma Biotechnology
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Earnings Call Luxembourg, SAVE 41% - pacificlanding.ca
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology Third Quarter 2022 Earnings: Beats Expectations
What Happened To Puma Biotechnology?
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
